VIOHALCO 17.660 € (+9,01 %) UMICORE 21.700 € (+0,56 %) CELYAD ONCOLOGY 0.231 € (-7,60 %) VAN DE VELDE 30.000 € (+1,01 %) GIMV 47.350 € (+0,21 %) ASCENCIO 52.700 € (-1,13 %) UCB 213.500 € (+0,66 %) D'IETEREN GROUP 161.900 € (-2,06 %) COLRUYT 38.920 € (+0,57 %) ONTEX GROUP 2.090 € (-2,56 %) KBC 132.950 € (-0,56 %) BPOST 1.178 € (-2,81 %) BREDERODE 105.800 € (0,00 %) TITAN S.A. 49.560 € (-0,56 %) ABO GROUP 4.000 € (-6,98 %) HOME INVEST BE. 17.940 € (+0,22 %) AGEAS 74.950 € (-2,22 %) TINC 10.980 € (-0,36 %) SYENSQO 79.050 € (+1,41 %) GBL 74.550 € (+0,20 %) KBC ANCORA 95.500 € (-0,31 %) FAGRON 22.200 € (+1,14 %) MONTEA 64.200 € (-0,31 %) ECONOCOM GROUP 1.420 € (-0,35 %) CMB.TECH 17.080 € (-1,39 %) TESSENDERLO 21.100 € (+3,43 %) SIPEF 108.600 € (-0,91 %) IMMOBEL 18.400 € (-0,81 %) MELEXIS 69.850 € (+2,72 %) ONWARD MEDICAL 2.785 € (-4,13 %) KINEPOLIS GROUP 50.800 € (+1,20 %) EKOPAK 3.470 € (+0,29 %) BARCO 7.495 € (+0,27 %) CIE BOIS SAUVAGE 303.000 € (0,00 %) HYLORIS 4.050 € (-3,57 %) NYXOAH 1.250 € (-3,99 %) SOLVAC NOM(RETAIL) 83.500 € (+1,83 %) VASTNED 28.250 € (+0,18 %) IBA 15.480 € (+0,13 %) LOTUS BAKERIES 12 620.000 € (+1,12 %) BEKAERT 38.350 € (+1,05 %) FLUXYS BELGIUM D 22.200 € (0,00 %) XIOR 25.400 € (+0,20 %) ELIA GROUP 120.400 € (+0,67 %) RETAIL ESTATES 65.000 € (+0,15 %) EVS 27.850 € (+2,01 %) AB INBEV 68.340 € (+0,71 %) AGFA-GEVAERT 0.381 € (-0,39 %) WAREHOUSES ESTATES 38.200 € (+2,41 %) PROXIMUS 6.230 € (-2,50 %) SOFINA 249.000 € (+1,06 %) JENSEN-GROUP 76.800 € (+2,13 %) DECEUNINCK 2.500 € (+1,01 %) VGP 71.500 € (-0,28 %) SOLVAY 25.360 € (+0,24 %) SHURGARD 23.600 € (+0,43 %) AEDIFICA 66.400 € (+0,91 %) ORANGE BELGIUM 22.100 € (+0,45 %) RECTICEL 12.720 € (+0,47 %) AZELIS GROUP 12.200 € (+1,92 %)
CEGEDIM 11.000 € (+2,04 %)
L'OREAL 389.500 € (+1,49 %)
LVMH 401.950 € (-0,88 %)
STMICROELECTRONICS 46.600 € (+4,37 %)
KERING 232.000 € (+1,47 %)
DSM FIRMENICH AG 97.120 € (+2,95 %)
SBM OFFSHORE 36.340 € (+0,33 %)
ASM INTERNATIONAL 860.800 € (+4,21 %)
ASML HOLDING 1 507.400 € (+1,76 %)
ADYEN 903.000 € (+1,35 %)
ORANGE 14.395 € (-4,13 %)
ING GROEP N.V. 31.700 € (-1,48 %)
AUBAY 51.900 € (-1,14 %)
ESSILORLUXOTTICA 144.500 € (+2,30 %)
ENGIE 23.800 € (+0,46 %)
EURONEXT 158.400 € (-0,81 %)
ENOGIA 6.380 € (0,00 %)
PERNOD RICARD 60.640 € (+1,68 %)
ETHERO 0.920 € (+8,24 %)
ALTAREA 84.900 € (+0,24 %)
ELIOR GROUP 1.880 € (-3,04 %)
HEIJMANS KON 86.100 € (-3,26 %)
KAUFMAN ET BROAD 21.500 € (+1,90 %)
ALSTOM 15.270 € (+2,11 %)
BUREAU VERITAS 27.800 € (+2,39 %)
ALPES (COMPAGNIE) 17.700 € (-1,45 %)
SHELL PLC 41.010 € (+0,58 %)
TELEPERFORMANCE 70.100 € (+0,26 %)
BASIC-FIT 31.600 € (-1,86 %)
EUROCOMMERCIAL 27.250 € (+1,68 %)
TIKEHAU CAPITAL 16.220 € (-2,99 %)
DANONE 60.900 € (+1,06 %)
CSG 15.134 € (-0,51 %)
AEGON 7.832 € (-1,76 %)
74SOFTWARE 38.200 € (-0,78 %)
Vusion 133.000 € (+13,68 %)
HERMES INTL 1 355.000 € (+0,82 %)
PEUGEOT INVEST 51.400 € (-1,72 %)
PLANISWARE 23.550 € (-0,42 %)
BE SEMICONDUCTOR 191.900 € (+1,72 %)
SODEXO 57.400 € (+0,61 %)
BROADPEAK 2.210 € (+0,45 %)
BIOMERIEUX 73.250 € (+1,31 %)
ARKEMA 57.500 € (+2,04 %)
GTT 222.600 € (-0,62 %)
VALNEVA 2.831 € (-0,77 %)
GROUPE GUILLIN 20.300 € (-1,46 %)
AXA 43.910 € (-2,07 %)
EXOR NV 71.450 € (+0,35 %)
NEXITY 5.240 € (+3,25 %)
BENETEAU 5.260 € (+1,54 %)
UNILEVER 54.840 € (+1,22 %)
WORLDLINE 12.202 € (+1,68 %)
VOPAK 47.000 € (-1,51 %)
AMUNDI 92.750 € (-0,27 %)
SAINT GOBAIN 71.220 € (+1,60 %)
PHARMING GROUP 0.964 € (+3,92 %)
SANOFI 74.390 € (-0,27 %)
IMCD 95.180 € (+1,34 %)
ID LOGISTICS GROUP 324.500 € (+1,25 %) News Réglementées
|
15/09/2026 09:00
Original-Research: MHP Hotel AG (von NuWays AG): BuyOriginal-Research: MHP Hotel AG - from NuWays AG Classification of NuWays AG to MHP Hotel AG
H1 optics are worse than operations; chg. Following Friday's guidance cut, MHP released its H1 report yesterday, confirming the picture. In detail: H1 sales came in at € 99.3m (eNuW: € 98.3m), up 25% yoy. Growth was significantly carried by the new hotels (Conrad and Hyatt Vienna), which added € 17m, implying organic growth of 3.8%. Occupancy came in at 72.0%, ADR at € 219 and RevPAR at € 158. Mind you, the reported rate data is adjusted for Conrad only. The Andaz Vienna was rebranded to Hyatt Regency over Easter, which both disrupted Q2 trading and structurally lowers portfolio ADR, so like-for-like rate erosion is materially smaller than the reported 1% decline suggests. Margin looks worse than it is. H1 EBITDA of € 0.2m was only slightly behind eNuW of € 0.6m. The H1'25 € 2.3m figure is actually not a good comparable, as it was inflated by € 4.0m Conrad FF&E related one-offs. Hence, there is no cost problem as operating EBITDA improved by € 1.9m yoy. Slower Conrad ramp-up and Middle East cause guidance cut. While the sales guidance was only slightly cut to € 220-225m (old: c. € 225m), EBITDA was adjusted more significantly from c. € 10m to c. € 8m. The main reason for this is seen to be the Conrad, where occupancy ramp-up is running below budget as flows through the brand systems have not materialized yet. On top of this comes Middle East. Although accounting for only 2.5% of sales (FY25 base), these guests are the usual suite bookers and carry well above-average F&B spend, causing a disproportionate earnings hit. Energy adds to the pressure, not only on pure price but also higher consumption during the summer heat. The implied H2 run-rate of € 7.8m however seems reasonable, in our view, as H2 is seasonally the far stronger half, with events like Oktoberfest and EXPO REAL carrying Q3 and December now among the portfolio's strongest months on Christmas market demand. Overall, the case is intact, as the cut is largely a timing issue (Conrad), not structural. Besides this, the company remains the leading white-label operator in the DACH premium segment, with privileged access to high-barrier assets that come with limited capital commitment of its own. This allows the platform to add about 1,000 rooms by FY29e without touching the balance sheet. With premium demand structurally unbroken and the Conrad ramp-up a question of when rather than if, the earnings power of the enlarged portfolio should come through from FY27e onwards. At current levels, the market is not at all pricing this. Changes in estimates reflect the FY26 guidance adjustment as well as a more conservate approach on return to normal from Middle East travellers. We thus reiterate BUY with a new PT of € 3.50 (old: € 3.70) based on DCF. You can download the research here: mhp-hotel-ag-2026-09-15-previewreview-en-028fb For additional information visit our website: https://www.nuways-ag.com/research Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse. ++++++++++ The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 2399172 15.09.2026 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||
© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière